博瑞医药首次披露4款创新药进展 热点“减肥药”三期临床试验进展顺利

Core Viewpoint - The company, Borui Biopharmaceuticals (Suzhou) Co., Ltd., has released its 2025 annual performance forecast, expecting a net profit attributable to shareholders of between 41.3 million and 61.9 million yuan, alongside significant updates on its innovative drug pipeline, particularly focusing on weight loss treatments [1]. Group 1: Financial Performance - The company anticipates a net profit of 41.3 million to 61.9 million yuan for 2025 [1]. Group 2: Innovative Drug Pipeline - The company has disclosed significant progress on seven innovative drugs, with four being newly announced [1]. - The injectable and oral formulations of BGM0504 for weight loss have shown notable advancements, with the injectable version completing all investments in domestic Phase III clinical trials and entering the administration and follow-up phase [1]. - The oral BGM0504 tablet has received IND approval in both China and the U.S., with the U.S. completing the last patient visit and China progressing towards the final dosing group follow-up [1]. Group 3: Newly Disclosed Projects - The announcement includes updates on four innovative drug projects: oral BGM1812, oral BGM1962, MSTN peptide injection, and ALK7 targeted siRNA [2][3]. - Oral BGM1812 is in preclinical research, utilizing an authorized oral peptide formulation platform with potential for weekly dosing [2]. - BGM1962, a novel long-acting selective agonist, is also in preclinical research, showing significant advantages in half-life and potential for monthly dosing [2]. - MSTN peptide injection aims to maintain or increase lean body mass while promoting weight loss, currently in the preclinical candidate stage [3]. - The ALK7 targeted siRNA project is designed for overweight/obesity indications, showing over 80% effective suppression of the ALK7 gene in non-human primates, also in the preclinical candidate stage [3]. Group 4: Strategic Focus - The company is focused on the metabolic field, with a forward-looking approach to multi-target combination therapies and innovative dosing frequencies, showcasing a competitive product pipeline [3].